385 related articles for article (PubMed ID: 24130167)
1. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
2. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
3. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.
Baena-Del Valle JA; Zheng Q; Esopi DM; Rubenstein M; Hubbard GK; Moncaliano MC; Hruszkewycz A; Vaghasia A; Yegnasubramanian S; Wheelan SJ; Meeker AK; Heaphy CM; Graham MK; De Marzo AM
J Pathol; 2018 Jan; 244(1):11-24. PubMed ID: 28888037
[TBL] [Abstract][Full Text] [Related]
4. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention.
Nelson WG; De Marzo AM; Deweese TL; Lin X; Brooks JD; Putzi MJ; Nelson CP; Groopman JD; Kensler TW
Ann N Y Acad Sci; 2001 Dec; 952():135-44. PubMed ID: 11795433
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
[TBL] [Abstract][Full Text] [Related]
6. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.
Koh CM; Gurel B; Sutcliffe S; Aryee MJ; Schultz D; Iwata T; Uemura M; Zeller KI; Anele U; Zheng Q; Hicks JL; Nelson WG; Dang CV; Yegnasubramanian S; De Marzo AM
Am J Pathol; 2011 Apr; 178(4):1824-34. PubMed ID: 21435462
[TBL] [Abstract][Full Text] [Related]
7. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
9. Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.
Narlik-Grassow M; Blanco-Aparicio C; Cecilia Y; Perez M; Muñoz-Galvan S; Cañamero M; Renner O; Carnero A
PLoS One; 2013; 8(4):e60277. PubMed ID: 23565217
[TBL] [Abstract][Full Text] [Related]
10. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway.
Chu J; Li Y; Deng Z; Zhang Z; Xie Q; Zhang H; Zhong W; Pan B
Biomed Res Int; 2019; 2019():7201562. PubMed ID: 31355278
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
[TBL] [Abstract][Full Text] [Related]
12. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
13. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.
Hahm ER; Singh KB; Singh SV
Cell Cycle; 2016 Sep; 15(17):2309-20. PubMed ID: 27341160
[TBL] [Abstract][Full Text] [Related]
14. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
15. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang E; Chen Z; Liu W; Lin L; Wu L; Guan J; Wang J; Kong C; Bi J; Zhang M
J Transl Med; 2024 Jan; 22(1):12. PubMed ID: 38166947
[TBL] [Abstract][Full Text] [Related]
16. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Maynard JP; Lu J; Vidal I; Hicks J; Mummert L; Ali T; Kempski R; Carter AM; Sosa RY; Peiffer LB; Joshu CE; Lotan TL; De Marzo AM; Sfanos KS
J Pathol; 2022 Feb; 256(2):149-163. PubMed ID: 34652816
[TBL] [Abstract][Full Text] [Related]
17. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
[TBL] [Abstract][Full Text] [Related]
18. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
19. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Ratliff TL
J Urol; 2005 Sep; 174(3):1149. PubMed ID: 16094083
[No Abstract] [Full Text] [Related]
20. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.
Ru P; Steele R; Nerurkar PV; Phillips N; Ray RB
Cancer Prev Res (Phila); 2011 Dec; 4(12):2122-30. PubMed ID: 21911444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
